Company intelligence / Profile preview
Spark Therapeutics
Philadelphia, Pennsylvania, United Statessparktx.com ↗
- Ownership
- Private
- Employees
- ~800
- Development stage
- Commercial
01
Overview
Spark Therapeutics has successfully commercialized the first gene therapy for a genetic disease in the U.S. (Luxturna for inherited retinal disease). Their hemophilia B therapy (fidanacogene elaparvovec) received FDA approval in 2024. Other programs are in various clinical stages.
- Therapeutic areas
- OphthalmologyHematologyRare DiseasesNeurology
- Modalities
- Gene therapyAAV vectors
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Pfizer (for hemophilia B gene therapy program)Genethon (licensed SPK-3006 construct)
Beyond the preview
Go deeper on Spark Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spark Therapeutics.